Voices
Hong Jae Chon: Integrating Systemic Therapy in the Earlier Stages of Liver Cancer
Hong Jae Chon/X

Hong Jae Chon: Integrating Systemic Therapy in the Earlier Stages of Liver Cancer

Hong Jae Chon, Director of Cancer Center, CHA Bundang Medical Center, shared a post on X:

“ICI moving to earlier stage of primary liver cancer Journal of Hepatology.

  • TACE + ICI: PFS improved across 4 RCTs, but OS immature
  • Neoadjuvant HCC: CARES-09 positive (HR 0.59)
  • Adjuvant HCC: IMbrave050 and KEYNOTE-937 negative
  • Adjuvant BTC: no RCT yet.”

Hong Jae Chon

Title: Integrating systemic therapy in the earlier stages of liver cancer

Authors: Julien Edeline, Ming Kuang, Maria Reig, Valérie Vilgrain

Read The Full Article

Hong Jae Chon

Other articles featuring Hong Jae Chon on OncoDaily.

Adjuvant Therapy Biliary tract cancer BTC cancer CARES-09 HCC hepatocellular carcinoma Hong Jae Chon ICI IMbrave050 Immune Checkpoint Inhibitors immunotherapy Journal of Hepatology Julien Edeline KEYNOTE-937 liver cancer Maria Reig Ming Kuang neoadjuvant therapy OncoDaily Oncology OS overall survival PFS primary liver cancer progression-free survival randomized controlled trial RCT Sun Yat-sen University SYSU TACE Unicancer Valérie Vilgrain